Accolade Welcomes Noom to Trusted Partner Ecosystem
Accolade (Nasdaq: ACCD) has announced a partnership with Noom to enhance its Trusted Partner Ecosystem. This collaboration offers a comprehensive solution for weight loss and metabolic health, integrating Noom's coaching with Accolade's primary care physicians. Noom Med, part of this partnership, focuses on obesity management, including GLP-1 medications and other anti-obesity drugs. Noom's approach combines psychology, science, and personalized support, achieving a 25% employee adoption rate and 42% of users maintaining weight loss for two years. This partnership aims to reduce obesity-related healthcare costs and improve outcomes through evidence-based care and advanced primary care support.
- Accolade's partnership with Noom expands its Trusted Partner Ecosystem, enhancing weight loss and metabolic health management.
- Noom's clinical obesity management solution, Noom Med, will be integrated with Accolade's primary care services, providing comprehensive care.
- The partnership aims to reduce healthcare costs associated with obesity, a significant business challenge for employers.
- Noom's approach has a proven track record, with 42% of users maintaining weight loss for at least two years and a 25% employee adoption rate.
- Accolade and Noom's combination of services targets the rising costs of GLP-1 utilization, addressing an 8.4% increase in pharmacy benefit costs.
- Noom Med's reliance on anti-obesity medications, including GLP-1s, could pose risks if not appropriately managed.
- The effectiveness of the partnership in reducing obesity-related healthcare costs remains to be seen and could impact employer adoption rates.
- Potential over-reliance on digital solutions and coaching for weight loss might not address all individual needs, leading to variable outcomes.
- The financial implications of integrating Noom's services with Accolade's existing infrastructure might lead to increased operational costs.
Insights
The partnership between Accolade and Noom integrates Noom's weight loss and metabolic health services into Accolade's primary care offerings. This alliance could lower healthcare costs for employers by addressing obesity-related conditions using evidence-based methods, including GLP-1 medications.
Short-term impact: This partnership enhances the perceived value of Accolade's offerings, potentially leading to increased customer acquisition and retention. It may positively influence Accolade's stock price due to anticipated cost savings for employers.
Long-term impact: If successful, this partnership could set a precedent for similar collaborations, positioning Accolade as a pioneer in integrating comprehensive care solutions. However, long-term success relies on the efficacy of these programs and sustained user engagement, which could be challenged by competition or evolving healthcare regulations.
Retail investors should monitor changes in customer acquisition rates and any reported outcomes on healthcare cost reductions over the coming quarters.
The combination of Noom's behavioral approach to weight loss with Accolade's primary care expertise is a unique strategy to combat obesity. Noom's approach, supported by psychological principles and digital tools, complements Accolade's clinical oversight.
Short-term insight: This partnership may result in better patient outcomes and enhanced adherence to treatment protocols, potentially reducing the financial burden of obesity-related conditions for employers. Positive clinical data arising from this collaboration could significantly bolster confidence in Accolade's healthcare solutions.
Long-term insight: The success of this initiative will depend on continuous innovation and the ability to adapt to new medical research and treatment modalities. The integration of GLP-1s and other medications requires careful monitoring to ensure patient safety and efficacy.
Investors should focus on clinical outcomes data and how well the integration of Noom's solutions into Accolade's ecosystem meets the anticipated health benefits and cost savings.
The partnership combines Noom's best-in-class content and coaching with Accolade's
advanced primary care physicians
Accolade and Noom's partnership offers employers a comprehensive, evidence-based model with personalized offerings for an employer's entire population, including connecting higher-risk members with Accolade physicians. This partnership empowers employers to stem the rising healthcare costs associated with obesity and its many comorbid conditions – and to ensure increasingly in-demand GLP-1s are appropriately prescribed and those taking them supported clinically.
Noom leverages psychology and science to drive behavioral change. Noom's enterprise solutions provide personalized, tailored support for members' unique weight loss journeys. Through a combination of informative content, nutrition, activity tracking tools, coaching, and community, Noom has proven to help people suffering from obesity lose at least
"In May 2023, responding to the marked increase in anti-obesity medication adoption, Noom launched Noom Med to provide high-quality clinical support to those suffering from the chronic disease of obesity," said Noom's CEO, Geoff Cook. "We put rigorous clinical protocols and a sophisticated technology platform in place to facilitate integration between physician-led care teams and our valuable content and coaching. Accolade's proven track record in primary care and building longitudinal relationships sets them apart – we see them as an ideal partner with whom to grow together."
When a member first engages with Noom, they'll complete a personalized assessment determining whether they're best served by (a) Noom Weight, a digital psychology-based weight management program, (b) Noom Diabetes Prevention Program, a tailored digital solution for those who show risk of diabetes - awarded full plus recognition by the CDC, or (c) Noom Med powered by Accolade, where Accolade physicians provide evidence-based obesity care that augments Noom's digital support. Non-GLP-1 anti-obesity medications are expected to be the initial course of action for nearly half of all participants. For more on the member experience, see here.
"When a member goes to Noom Med powered by Accolade, we ensure that the right members are gaining access to GLP-1s or other anti-obesity treatment and that members are making the behavior and lifestyle changes necessary to, where appropriate, successfully taper off those medications," said Dr. James Wantuck, Accolade Chief Medical Officer. "Our customers and members will benefit from Accolade's physician-led model combined with Noom's best-in-class content, coaching, and community. This innovative combination will drive sustainable weight-loss outcomes and reduce inappropriate spending."
Obesity is a significant health and business challenge. Nationwide obesity rates have more than tripled since the 1960s, with the current estimated rate at
Accolade's Trusted Partner Ecosystem Increases Digital Solution Engagement
Launched in 2019, Accolade's Trusted Partner Ecosystem accelerates the performance of digital health solutions to improve outcomes across valued categories for employers. Accolade's ecosystem currently consists of 18 partners across 11 categories.
Benefits teams can confidently select from thoroughly vetted solutions and enjoy streamlined contracting and implementation. Through qualified referrals, Accolade drives more engagement with partner solutions, leading to exponentially better health outcomes and better value. Learn more here.
About Accolade
Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinions, and best-in-class care navigation. These offerings are built on a platform engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over
About Noom
Noom is the digital healthcare company empowering people to live better, longer lives. Noom connects people to content, coaching, community, and clinicians to improve whole-person health. Noom also works with leading employers, health plans, and health systems, offering Noom Med, Noom GLP-1 Companion, Noom Weight, Noom Diabetes Prevention Program, and Noom Mood to millions of covered lives. The company has been awarded multiple grants from the National Institutes of Health and was the first mobile application to be recognized by the Centers for Disease Control and Prevention as a certified diabetes prevention program. With offices in
View original content to download multimedia:https://www.prnewswire.com/news-releases/accolade-welcomes-noom-to-trusted-partner-ecosystem-302151148.html
SOURCE Accolade, Inc.
FAQ
What is the purpose of Accolade's partnership with Noom announced on May 21, 2024?
How does Noom Med, powered by Accolade, support weight loss?
What are the expected outcomes of the Noom and Accolade partnership?
How effective is Noom's approach to weight loss?
What impact does the Accolade and Noom partnership have on GLP-1 medication utilization?
